BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Deferasirox

A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.

298+ PubMed studies analyzed · 31 RCTs · Evidence Score: 52.8

Research Domains

Deferasirox has been studied across 15 research domains including 🫁 Liver & Detox, 🫘 Kidney, 🔬 Oncology, ⏳ Longevity & Aging, 🔬 Inflammation. The primary research focus is 🫁 Liver & Detox with 11% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Deferasirox, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Itraconazole
13 shared targets
Methandrostenolone
11 shared targets
Polidocanol
14 shared targets
Pregnenolone
11 shared targets
Melengestrol
12 shared targets
Decitabine
10 shared targets
Ethynodiol
15 shared targets
Proscillaridin
11 shared targets
Methyltestosterone
12 shared targets
Dydrogesterone
10 shared targets
Loading evidence profile...

This evidence profile for Deferasirox is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.